Vor Biopharma Inc. (VOR)
After hours:
| Previous close | 1.7000 |
| Open | 1.7100 |
| Bid | 1.6700 x 500 |
| Ask | 1.7000 x 500 |
| Day's range | 1.6500 - 1.7100 |
| 52-week range | 1.6200 - 5.7000 |
| Volume | |
| Avg. volume | 324,971 |
| Market cap | 115.285M |
| Beta (5Y monthly) | -0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7500 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.69 |
ZacksWhy You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Simply Wall St.Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
GlobeNewswireVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2023, and provided a business update. “We are very pleased w
